Catalyst Dossier · compiled by Celia 🧫

Kyowa Kirin Co., Ltd. (4151.T)

Biotechnology · market cap $1310.8B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Kyowa Kirin Co., Ltd. (4151.T) is a Japan-listed biotechnology company with approximately 5,669 employees and a reported market capitalization of roughly $1.31 trillion (JPY-denominated, likely reflecting yen figures). The company operates a broad clinical pipeline spanning nephrology, neurology, oncology, dermatology, and rare diseases, with the designated lead asset being Cinacalcet HCl in Phase 3 for Parathyroid Carcinoma, alongside multiple Phase 2 and Phase 3 programs. Near-term catalysts include Phase 2 readouts for KHK4951 (nAMD) in August 2026 and two additional Phase 2 data points in early-to-mid 2027.

The catalyst path

2026-08-31 (est.)Phase 2 · KHK4951imp 7/10
2027-03-15 (est.)Phase 2 · ziftomenibimp 7/10
2027-04-15 (est.)Phase 2 · KK2430imp 7/10

Pipeline

Asset	Phase	Indication
KHK4083	Phase 2	Ulcerative Colitis
KHK6188	Phase 2	Postherpetic Neuralgia
Cinacalcet HCl	Phase 3	Parathyroid Carcinoma
RTA 402	Phase 2	Chronic Kidney Disease
Entinostat	Phase 2	Advanced or Recurrent Breast Cancer
KRN1493	Phase 3	Secondary Hyperparathyroidism
KHK4951	Phase 2	Neovascular Age-Related Macular Degeneration (nAMD)
Istradefylline (KW-6002)	Phase 3	Parkinson's Disease
VCAP/AMP/VECP(mLSG15)	Phase 2	Adult T-cell Leukemia-Lymphoma
KW-0761	Phase 2	Peripheral T/NK-cell Lymphoma
KHK4827	Phase 3	Moderate to Severe Systemic Sclerosis
KHK4827 140mg SC	Phase 3	Psoriasis Vulgaris
OPC-262	Phase 3	Type 2 Diabetes
Antithrombin gamma	Phase 3	Preeclampsia
KHK4577	Phase 2	Atopic Dermatitis
KHK7791	Phase 3	Hyperphosphatemia
KRN23	Phase 3	X-linked Hypophosphatemia
KW-6356	Phase 2	Parkinson's Disease
Istradefylline 20 mg or 40 mg	Phase 3	Idiopathic Parkinson's Disease
AMG 531	Phase 3	Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.